The M⁶A Epitranscriptome: A Regulatory Nexus Linking Cellular Senescence And Oncogenesis
Our cells contain a fascinating layer of regulation beyond our DNA sequence, known as the epitranscriptome. One key player in this system is N⁶-methyladenosine, or m⁶A, a common chemical tag found on RNA molecules. Think of m⁶A as a tiny switch that can change how our RNA behaves. These switches are added by “writer” proteins, removed by “eraser” proteins, and recognized by “reader” proteins, all working together to control the fate of RNA, including its stability and how it’s translated into proteins.
Recent research highlights that this m⁶A system is a critical link between cellular aging, known as senescence, and the development of cancer. Senescence is when cells stop dividing and undergo changes, contributing to aging and age-related diseases. The m⁶A modifications can fine-tune the pathways involved in this cellular aging process.
Intriguingly, m⁶A also plays a complex, dual role in cancer. Depending on the cellular context, it can either act as a protective mechanism against tumors or, conversely, promote tumor growth, spread, and resistance to treatments. Disruptions in the balance of m⁶A “writers,” “erasers,” and “readers” are frequently observed in various cancers, leading to altered gene expression that drives the disease.
Furthermore, m⁶A’s regulatory power is closely intertwined with non-coding RNAs—molecules that don’t make proteins but are vital for gene regulation. These include microRNAs, long non-coding RNAs, and circular RNAs. m⁶A can influence how these non-coding RNAs are produced, how long they last, and how they function, creating intricate feedback loops that contribute to cancer progression.
Understanding these complex interactions opens up exciting new avenues for medicine. Scientists are now exploring ways to target the m⁶A system with new therapies, such as specific inhibitors, to develop combined anti-cancer and anti-aging treatments. This research offers promising strategies for precision medicine, aiming to tackle both cancer and age-related diseases by modulating these fundamental RNA modifications.
Source: link to paper